Umbilical cord

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Global Cord Blood Corporation of Class Action Lawsuit and Upcoming Deadlines - CORBF

Retrieved on: 
Samedi, juin 15, 2024

NEW YORK, June 15, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Global Cord Blood Corporation ("Global Cord" or the "Company") (OTC: CORBF) and certain officers.

Key Points: 
  • NEW YORK, June 15, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Global Cord Blood Corporation ("Global Cord" or the "Company") (OTC: CORBF) and certain officers.
  • Originally known as "China Cord Blood Corporation,"  Global Cord became a public company in May 2007 and began trading on the New York Stock Exchange ("NYSE") in November 2009.
  • Global Cord and Golden Meditech also maintained the same registered address in Hong Kong, even occupying the same building floor.
  • Similarly, Kam continued to exert control over Global Cord after he was no longer formally associated with the Company.

We dated a sacred Aboriginal women’s site used for birthing ceremonies and discovered 7,000 years of tool making

Retrieved on: 
Vendredi, juin 14, 2024

We detail our findings in newly published research in collaboration with archaeological expert Liz Hatte and Jangga Elders Colin McLennan and Marie Wallace.

Key Points: 
  • We detail our findings in newly published research in collaboration with archaeological expert Liz Hatte and Jangga Elders Colin McLennan and Marie Wallace.
  • Our excavation of the layered sediments at Avon Downs reveals a long history of raw stone extraction and tool making.
  • By dating these artefacts, we have traced a 7,000-year history of continuous stone tool production by Aboriginal women – including objects traditionally associated with men.

Hundreds of generations of tool making

  • This implies the site was used for stone tool production and possibly as a sacred women’s area for hundreds of generations.
  • Jangga Elders Colin McLennan and Marie Wallace have a shared memory extending as far back as at least six generations.
  • Drill points, ochre and a grinding stone and muller are further evidence of everyday tool making and decoration.

Railway project disruptions

  • It sits in the way of the North Galilee Basin Rail Project, which stretches from the Carmichael coal mine to the port at Abbot Point.
  • Planning for this project started in 2012, prompting cultural heritage surveys, assessments and negotiations with Traditional Owners.
  • So while the railway project will not run directly through, it has still compromised the integrity of the area.

Protecting sacred area

  • Sacred Aborignal women’s sites are often difficult to protect in their entirety.
  • Throughout Australia, there are only a handful of examples where Aboriginal women have chosen to disclose secret information to protect sacred women’s sites for future generations.
  • When explaining the importance of protecting and recording Jangga traditional knowledge and culture, Wallace emphasised the Jangga people’s belief that such sacred places can even be dangerous: You are not supposed to touch anything, or take away something.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Global Cord Blood Corporation of Class Action Lawsuit and Upcoming Deadlines – CORBF

Retrieved on: 
Mardi, mai 28, 2024

NEW YORK, May 28, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Global Cord Blood Corporation (“Global Cord” or the “Company”) (OTC: CORBF) and certain officers.

Key Points: 
  • NEW YORK, May 28, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Global Cord Blood Corporation (“Global Cord” or the “Company”) (OTC: CORBF) and certain officers.
  • Originally known as “China Cord Blood Corporation,” Global Cord became a public company in May 2007 and began trading on the New York Stock Exchange (“NYSE”) in November 2009.
  • Global Cord and Golden Meditech also maintained the same registered address in Hong Kong, even occupying the same building floor.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against GoodRx, Autodesk, Global Cord, and Lincoln and Encourages Investors to Contact the Firm

Retrieved on: 
Mercredi, mai 8, 2024

Critically, however, Defendants never informed investors of the material risk that Kroger, which accounted for nearly 25% of GoodRx’s prescription transactions revenue, could unilaterally refuse to accept GoodRx’s discounts.

Key Points: 
  • Critically, however, Defendants never informed investors of the material risk that Kroger, which accounted for nearly 25% of GoodRx’s prescription transactions revenue, could unilaterally refuse to accept GoodRx’s discounts.
  • Global Cord and Golden Meditech also maintained the same registered address in Hong Kong, even occupying the same building floor.
  • Following the appointment of the Joint Provisional Liquidators, the NYSE halted trading in Global Cord's ordinary shares, effective September 23, 2022.
  • For more information on the Lincoln class action go to: https://bespc.com/cases/LNC

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against HireRight, Doximity, Global Cord, and Lincoln Innovations and Encourages Investors to Contact the Firm

Retrieved on: 
Samedi, mai 4, 2024

For more information on the HireRight class action go to: https://bespc.com/cases/HRT

Key Points: 
  • For more information on the HireRight class action go to: https://bespc.com/cases/HRT
    Doximity operates a digital platform that provides connections between, medical information to, and patient scheduling tools for medical professionals.
  • Global Cord and Golden Meditech also maintained the same registered address in Hong Kong, even occupying the same building floor.
  • This was compared to a net income of $318 million for the third quarter of 2021 the previous year.
  • For more information on the Lincoln class action go to: https://bespc.com/cases/LNC

GLOBAL CORD ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Global Cord Blood Corporation and Encourages Investors to Contact the Firm

Retrieved on: 
Vendredi, avril 26, 2024

Investors have until June 21, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until June 21, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • The Company has received but rejected multiple "going private" offers, or transactions in which a public company is converted into private ownership.
  • Golden Meditech's previous financial interest in Global Cord is just one of the significant connections that have existed between the two companies during the relevant time.
  • Global Cord and Golden Meditech also maintained the same registered address in Hong Kong, even occupying the same building floor.

Celularity Announces Net Sales Trending Ahead of Expectations for First Quarter 2024; Implements Planned 2024 SG&A Reductions and Manufacturing Ramp for Advanced Biomaterial Products

Retrieved on: 
Lundi, avril 15, 2024

FLORHAM PARK, N.J., April 15, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ: CELU) (“Celularity”) a regenerative medicine company developing placental-derived allogeneic cell therapies and advanced biomaterial products, today announced that its expected net sales for the first quarter of 2024 are trending ahead of the expectations it announced in February for its advanced biomaterial products and biobanking businesses.

Key Points: 
  • Celularity’s predecessor company was an early innovator in the field of placental-derived biomaterials, and today we continue to develop innovative, next-generation products in this technology.
  • Under the plan implemented, senior executives are foregoing a portion of their 2024 cash salary as well as payment in cash of any performance bonus payable in 2024.
  • Celularity’s advanced biomaterial product pipeline consists of four commercial-stage products and three investigational products.
  • Interfyl®, a decellularized human placental connective tissue matrix designed for use to replace or supplement damaged or inadequate integumental tissue.

Orphan designation: melatonin Treatment of perinatal asphyxia, 02/04/2012 Positive

Retrieved on: 
Mardi, avril 9, 2024

Overview

Key Points: 
  • Overview
    On 2 April 2012, orphan designation (EU/3/12/978) was granted by the European Commission to Dr Nicola J Robertson, United Kingdom, for melatonin for the treatment of perinatal asphyxia.
  • At the time of orphan designation, there was no treatment for perinatal asphyxia authorised in the EU.
  • Key facts
    - Active substance
    - melatonin
    - Intended use
    - Treatment of perinatal asphyxia
    - Orphan designation status
    - Positive
    - EU designation number
    - EU/3/12/978
    - Date of designation
    - Sponsor
    UCL Research Limited
    Review of designation
    The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.
  • EU register of orphan medicines
    The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

Orphan designation: haematopoietic stem cells and blood progenitors umbilical cord-derived expanded with (1R, 4R)-N1-(2-benzyl-7-(2-methyl-2H-tetrazol-5-yl)-9H-pyrimido[4,5-b]indol-4-yl)cyclohexane-1,4-diamine dihydrobromide dihydrate Treatment in ha[...]

Retrieved on: 
Mardi, avril 9, 2024

Orphan designation: haematopoietic stem cells and blood progenitors umbilical cord-derived expanded with (1R, 4R)-N1-(2-benzyl-7-(2-methyl-2H-tetrazol-5-yl)-9H-pyrimido[4,5-b]indol-4-yl)cyclohexane-1,4-diamine dihydrobromide dihydrate Treatment in haematopoietic stem cell transplantation, 20/04/2020 Positive

Key Points: 


Orphan designation: haematopoietic stem cells and blood progenitors umbilical cord-derived expanded with (1R, 4R)-N1-(2-benzyl-7-(2-methyl-2H-tetrazol-5-yl)-9H-pyrimido[4,5-b]indol-4-yl)cyclohexane-1,4-diamine dihydrobromide dihydrate Treatment in haematopoietic stem cell transplantation, 20/04/2020 Positive

Global Cord Blood & Tissue Banking Industry Market Size, Segmentation & Forecast Report 2024 - ResearchAndMarkets.com

Retrieved on: 
Vendredi, mars 15, 2024

The "Global Cord Blood & Tissue Banking Industry Report - Market Size, Segmentation, & Forecasts, 2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Cord Blood & Tissue Banking Industry Report - Market Size, Segmentation, & Forecasts, 2024" report has been added to ResearchAndMarkets.com's offering.
  • There are now over 800,000 cord blood units stored in public cord blood banks and more than 6.75 million cord blood and tissue units stored within private banks worldwide.
  • Today, nearly all U.S. cord blood banks and approximately one-third of global cord blood banks offer cord tissue storage.
  • The report presents findings on the following topics:
    Rate per cord blood unit in the U.S. and Europe
    Number of clinical trials, number of published scientific papers, and amount of NIH funding for cord blood research
    Number and types of patents for cord blood, cord tissue, and placental products
    The report presents a comprehensive analysis of the global cord blood and tissue banking market.